FDA MDDT Program: Qualification & Guidelines

Note: This guide provides regulatory, methodological, and administrative reference information for researchers, medical device developers, and academic consortia. It does not constitute individual clinical advice or legal counsel.

What it is and who runs it

The Medical Device Development Tool (MDDT) program is a voluntary regulatory qualification program operated by the Center for Devices and Radiological Health (CDRH) within the U.S. Food and Drug Administration (FDA). As described on the official page on 2026-11-07, the program establishes a formal mechanism for FDA CDRH to evaluate and qualify tools used by medical device developers to assess device safety, clinical effectiveness, or performance.

Authorized under Section 514(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and formally established pursuant to Section 507 as enacted by the 21st Century Cures Act, the MDDT program addresses a persistent bottleneck in medical device development. Traditionally, when a sponsor incorporates a novel bench-test method, computer simulation model, or patient survey into a premarket regulatory filing, the FDA must evaluate both the device and the underlying methodology used to test it. Formal qualification through the MDDT program decouples tool validation from individual device submissions, providing transparent, standardized assessment methods for the entire biomedical community.

Eligibility

According to FDA CDRH program guidelines, eligibility for MDDT qualification is open to any individual, research organization, commercial entity, medical society, or non-profit consortium that develops or validates methods to evaluate medical devices. There are no corporate size restrictions or geographical exclusions, provided the submission is presented in English and satisfies administrative requirements.

To qualify as an eligible tool, the proposed methodology must fall into one of three defined categories:

Clinical Outcome Assessments (COAs): Instruments that measure how a patient feels, functions, or survives. COAs encompass Patient-Reported Outcome (PRO) measures (such as standardized health-related quality of life questionnaires), Clinician-Reported Outcome (ClinRO) measures, Observer-Reported Outcome (ObsRO) measures, and Performance Outcome (PerfO) tasks. Digital health measurement technologies (DHTs) and wearable sensors tracking patient functional endpoints can also be qualified under this category.
Biomarker Tests: Laboratory assays, medical imaging methods, or physiological measurements processed to serve as an indicator of normal biological processes, pathogenic states, or clinical responses to an intervention. In the medical device domain, biomarker tests evaluate device-tissue interactions, hemocompatibility, or patient stratification for clinical investigations.
Non-Clinical Assessment Models (NAMs): In vitro bench-test systems, ex vivo organ models, in vivo animal models, or in silico computational models and simulation software that evaluate physical, mechanical, thermal, electrical, or biological performance. NAMs frequently replace, reduce, or refine animal or human testing.

What it funds or requires

The MDDT program is not a grant-awarding funding mechanism; it does not distribute direct financial capital to tool developers. Instead, it is a non-monetary regulatory facilitation program that carries zero FDA user fees. Developers bear their own research and development costs to generate the required validation data, but they incur no application charges when submitting tools to CDRH for qualification.

As described on the official page on 2026-11-07, what the program strictly requires is empirical scientific substantiation supporting a defined Context of Use (COU). The Context of Use is the foundational boundary of qualification. It explicitly delineates:

The specific role of the tool in medical device development (e.g., patient enrichment in medical device clinical trials, non-clinical safety testing, or premarket diagnostic performance).
The target device type, anatomical location, or operational mechanism (e.g., assessing radiofrequency-induced heating in active implantable medical devices during magnetic resonance imaging).
The target patient population and disease state (e.g., measuring functional limitation in adult patients with chronic heart failure).
The precise regulatory submission pathway where the tool will be applied, including Premarket Approval (PMA) and 510(k) submissions, De Novo requests, or Investigational Device Exemption (IDE) applications.

When CDRH qualifies a tool, it qualifies it exclusively for that bounded Context of Use. Any use outside that defined scope requires independent validation by the device sponsor.

Application or compliance steps

Engaging with the MDDT program follows a standardized, two-phase administrative submission workflow managed through the CDRH Customer Collaboration Portal:

Step 1: Informal Engagement and UTN Request: Submitters request a Universal Tracking Number (UTN) through the CDRH Portal and may request an informal preliminary discussion with CDRH staff to gauge tool suitability before assembling formal documentation.
Step 2: Proposal Package Submission (Phase 1): The applicant submits a comprehensive Proposal Package containing:
- Cover letter and administrative contact details.
- Comprehensive description of the tool, its concept of interest, and its measurement mechanism.
- Proposed Context of Use (COU) statement.
- Specific performance characteristics and acceptance criteria (precision, reproducibility, accuracy, sensitivity, and measurement limits).
- A detailed Qualification Plan outlining the empirical protocols, data collection frameworks, and statistical plans that will be executed to prove the tool meets its performance criteria.
- An assessment of the tool’s advantages and known operational limitations.
Step 3: CDRH Proposal Review: CDRH multidisciplinary review teams evaluate the proposal, aiming to issue a decision within 90 calendar days. If accepted, CDRH issues an acceptance letter agreeing to the Qualification Plan and Context of Use.
Step 4: Execution and Full Qualification Package Submission (Phase 2): The submitter executes the agreed Qualification Plan, compiling full validation reports, bench test data, or clinical datasets into a Full Qualification Package. This submission includes a draft Summary of Evidence and Basis of Qualification (SEBQ).
Step 5: CDRH Full Review and Public Listing: CDRH evaluates the complete evidentiary dossier. Upon approval, the FDA issues a formal qualification letter and publishes the tool’s details along with a public SEBQ on the FDA MDDT website.

Typical timeline phases

The qualification process typically advances across three major chronological phases rather than fixed calendar schedules, depending heavily on the complexity of the evidentiary dataset:

Proposal Phase (Typically 3 to 6 months): Preparation of the proposal package by the developer followed by CDRH review. FDA internal performance goals aim to complete the review of a complete Proposal Package within approximately 90 days of receipt, which may include iterative clarifications or refinement of the Context of Use statement.
Study Execution and Data Gathering Phase (Variable: 6 to 24 months): The duration of this phase is dictated entirely by the applicant’s research pace. Computational simulation models and bench phantom validations may execute within several months, whereas multi-center clinical outcome assessments or longitudinal biomarker validations frequently require 12 to 24 months of data collection.
Full Qualification Review Phase (Typically 6 to 12 months): Once the Full Qualification Package is submitted, CDRH conducts an in-depth scientific review of the raw datasets, statistical models, and protocol adherence. If the evidence satisfies CDRH standards, the formal qualification is granted.

Common mistakes

CDRH feedback and regulatory reviews highlight several recurring errors that lead to delays or rejection of MDDT submissions:

Overly Broad or Vague Context of Use: Attempting to qualify a tool for “all orthopedic implants” or “general cardiac monitoring.” CDRH requires narrow, well-characterized boundaries specifying device classes, anatomical locations, and patient subgroups.
Conflating Tool Qualification with Device Clearance: Assuming that an MDDT qualification constitutes marketing clearance for a standalone commercial device. An MDDT qualification is strictly a regulatory science endorsement for an evaluation tool; it does not permit marketing a diagnostic device for direct clinical patient care.
Inadequate Characterization of Measurement Error: Failing to report test-retest reliability, inter-operator variability, or computational mesh convergence limits for in silico models.
Uncontrolled Modifications During Phase 2: Altering software algorithms, survey item wording, or bench-test fixturing mid-validation without consulting CDRH, which compromises the integrity of the agreed Qualification Plan. Tool developers should align their testing processes with formal design controls and human factors and usability engineering principles.

Related programs

The MDDT program is one of several regulatory science initiatives established by the FDA to accelerate therapeutic and device development. The table below compares MDDT against adjacent regulatory and qualification pathways.

Program	Lead FDA Center	Focus Area	Primary Mechanism
Medical Device Development Tools (MDDT)	CDRH	Medical devices, software, diagnostics, and implants	Two-phase qualification (Proposal & Qualification) for COAs, Biomarkers, and NAMs
Drug Development Tool (DDT) Qualification Program	CDER / CBER	Small-molecule pharmaceuticals and therapeutic biologics	Three-phase qualification for Biomarkers, Clinical Outcome Assessments, and Animal Models
Standards and Conformity Assessment Program (ASCA)	CDRH	Medical device consensus standards testing	Accreditation of third-party testing laboratories to assess compliance with FDA-recognized consensus standards
CDRH Total Product Life Cycle Advisory Program (TAP)	CDRH	Breakthrough Devices	Early strategic engagement among innovators, FDA review staff, payers, clinicians, and patient groups

Device manufacturers leveraging qualified MDDT tools frequently integrate their findings into electronic regulatory submissions using the eSTAR FDA submission template, referencing the tool’s public UTN to streamline premarket review.

Frequently asked questions

What is the primary benefit of using an FDA-qualified MDDT?

The primary benefit is regulatory predictability and streamlined submission review. When a medical device sponsor uses a qualified MDDT within its approved Context of Use, CDRH reviewers accept the tool’s validity without requiring the sponsor to submit primary validation data for the tool itself.

Can anyone use a qualified MDDT once it is approved?

Yes. Once an MDDT is officially qualified by CDRH, a public Summary of Evidence and Basis of Qualification (SEBQ) is published. Any medical device sponsor may reference and use that qualified tool within its approved Context of Use in their own premarket submissions.

Does the FDA charge application fees for MDDT qualification?

No. The MDDT program is completely voluntary and free of FDA user fees. Sponsoring organizations fund their own internal research, bench testing, and clinical validation studies, but no MDUFA user fees apply to the submission or review of MDDT packages.

What is an example of an FDA-qualified MDDT?

Prominent examples include the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome measure qualified to evaluate functional status and quality of life in heart failure device trials, and IMAnalytics with MRIxViP, a computational modeling tool qualified to assess MRI radiofrequency heating of active medical implants.

Sources

U.S. Food and Drug Administration. (2017, August). Qualification of Medical Device Development Tools: Guidance for Industry, Tool Developers, and Food and Drug Administration Staff. Center for Devices and Radiological Health. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-medical-device-development-tools (Read: 2026-11-07).
U.S. Food and Drug Administration. (2026, November 7). Medical Device Development Tools (MDDT). Center for Devices and Radiological Health. https://www.fda.gov/medical-devices/medical-device-development-tools-mddt (Read: 2026-11-07).
U.S. Food and Drug Administration. (2026, November 7). Qualified Medical Device Development Tools (MDDTs). Center for Devices and Radiological Health. https://www.fda.gov/medical-devices/medical-device-development-tools-mddt/qualified-medical-device-development-tools (Read: 2026-11-07).
United States Congress. Federal Food, Drug, and Cosmetic Act, Section 507 [21 U.S.C. 360a-2] — Qualification of Drug and Device Development Tools. Enacted by the 21st Century Cures Act. (Read: 2026-11-07).